Biotech company Vertex Pharmaceuticals (NASDAQ: VRTX) beat Wall Street’s revenue expectations in Q1 CY2026, with sales up 7.8% year on year to $2.99 billion. The company expects the full year’s revenue to be around $13.03 billion, close to analysts’ estimates. Its non-GAAP profit of $4.47 per share was 3.8% above analysts’ consensus estimates.
Is now the time to buy Vertex Pharmaceuticals? Find out by accessing our full research report, it’s free.
Vertex Pharmaceuticals (VRTX) Q1 CY2026 Highlights:
- Revenue: $2.99 billion vs analyst estimates of $2.95 billion (7.8% year-on-year growth, 1.2% beat)
- Adjusted EPS: $4.47 vs analyst estimates of $4.31 (3.8% beat)
- Adjusted Operating Income: $1.31 billion vs analyst estimates of $1.25 billion (43.9% margin, 5.2% beat)
- The company reconfirmed its revenue guidance for the full year of $13.03 billion at the midpoint
- Operating Margin: 38.1%, up from 22.7% in the same quarter last year
- Market Capitalization: $107.8 billion
“Vertex is off to a strong start in 2026, driven by leadership in cystic fibrosis; growth in sickle cell disease, beta thalassemia, and acute pain; as well as rapid pipeline progress,” said Reshma Kewalramani, M.D., Chief Executive Officer and President of Vertex.
Company Overview
Founded in 1989 with a mission to create medicines that treat the underlying causes of disease rather than just symptoms, Vertex Pharmaceuticals (NASDAQ: VRTX) develops and markets transformative medicines for serious diseases, with a focus on cystic fibrosis, sickle cell disease, and pain management.
Revenue Growth
A company’s long-term sales performance is one signal of its overall quality. Even a bad business can shine for one or two quarters, but a top-tier one grows for years. Luckily, Vertex Pharmaceuticals’s sales grew at a solid 13.8% compounded annual growth rate over the last five years. Its growth beat the average healthcare company and shows its offerings resonate with customers, a helpful starting point for our analysis.
Long-term growth is the most important, but within healthcare, a half-decade historical view may miss new innovations or demand cycles. Vertex Pharmaceuticals’s annualized revenue growth of 9.5% over the last two years is below its five-year trend, but we still think the results were respectable. 
This quarter, Vertex Pharmaceuticals reported year-on-year revenue growth of 7.8%, and its $2.99 billion of revenue exceeded Wall Street’s estimates by 1.2%.
Looking ahead, sell-side analysts expect revenue to grow 8.3% over the next 12 months, similar to its two-year rate. We still think its growth trajectory is attractive given its scale and suggests the market sees success for its products and services.
ONE MORE THING: The $21 AI Application Stock Wall Street Forgot. While Wall Street obsesses over who’s building AI, one company is already using it to print money. And nobody’s paying attention.
AI chip stocks trade at ridiculous valuations. This company processes a trillion consumer signals monthly using AI and trades at a third of the price. The gap won’t last. The institutions will figure it out. You need to see this first. Read the FREE Report Before They Notice.
Adjusted Operating Margin
Adjusted operating margin is a key measure of profitability. Think of it as net income (the bottom line) excluding the impact of non-recurring expenses, taxes, and interest on debt - metrics less connected to business fundamentals.
Vertex Pharmaceuticals has been a well-oiled machine over the last five years. It demonstrated elite profitability for a healthcare business, boasting an average adjusted operating margin of 36.9%.
Looking at the trend in its profitability, Vertex Pharmaceuticals’s adjusted operating margin rose by 1 percentage points over the last five years, as its sales growth gave it operating leverage. Zooming into its more recent performance, however, we can see the company’s margin has decreased by 3.1 percentage points on a two-year basis. Given its business quality, we’re optimistic that Vertex Pharmaceuticals can correct course and return to expansion.
In Q1, Vertex Pharmaceuticals generated an adjusted operating margin profit margin of 43.9%, up 1.2 percentage points year on year. This increase was a welcome development and shows it was more efficient.
Earnings Per Share
We track the long-term change in earnings per share (EPS) for the same reason as long-term revenue growth. Compared to revenue, however, EPS highlights whether a company’s growth is profitable.
Vertex Pharmaceuticals’s remarkable 11.9% annual EPS growth over the last five years aligns with its revenue performance. This tells us its incremental sales were profitable.
In Q1, Vertex Pharmaceuticals reported adjusted EPS of $4.47, up from $4.06 in the same quarter last year. This print beat analysts’ estimates by 3.8%. Over the next 12 months, Wall Street expects Vertex Pharmaceuticals’s full-year EPS of $18.82 to grow 4.2%.
Key Takeaways from Vertex Pharmaceuticals’s Q1 Results
It was good to see Vertex Pharmaceuticals narrowly top analysts’ revenue expectations this quarter. We were also glad its EPS outperformed Wall Street’s estimates. Zooming out, we think this was a decent quarter. Investors were likely hoping for more, and shares traded down 1.1% to $425.73 immediately after reporting.
Big picture, is Vertex Pharmaceuticals a buy here and now? When making that decision, it’s important to consider its valuation, business qualities, as well as what has happened in the latest quarter. We cover that in our actionable full research report which you can read here (it’s free).
